НŢ

PTO/SB/21 (09-04)

	U.S. P	alast and Tr	Approved for use through 07/31/2006. OMS 0851-0031 Bdemark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person	Application Number	10/035,7	
TRANSMITTAL	Filing Date		er 24, 2001 PECELVE
FORM	First Named Inventor		GRAUPE et al. CENTRAL FAX CENTE
1 OKW	Art Unit	1626	
	Examiner Name	SHIAO,	Rei Tsang JAN 0 4 2005
(to be used for all correspondence after initial filling)	Attorney Docket Number	USAV20	001/0081 US NP
Total Number of Pages In This Submission			
ENC	LOSURES (Check all	that apply	After Allowance Communication to TC
Fee Transmittal Form	Drawing(s)		After Allowance Communication to 10
Fee Attached	Ucensing-related Papers		Appeal Communication to Board of Appeals and Interferences
	Pelition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
Amendment/Reply	Pelifion to Convert to a		Proprietary Information
After Final	Provisional Application Power of Attorney, Revocation	n	
Affidavits/declaration(s)	Change of Correspondence A		Status Letter Other Enclosure(s) (please identify
Extension of Time Request	Terminal Disdalmer		Other Enclosure(s) (please identity below):
Express Abandonment Request	Request for Refund		1. Form 1449 2. Transmittal of IDS Fee Form
Information Disclosure Statement	CD, Number of CD(s)		
	Landscape Table on CD		
Certified Copy of Priority Remi	arks		
Document(s)			į.
Reply to Missing Parts/ Incomplete Application			
Reply to Missing Parts under 37 CFR 1.52 or 1.53	•		·
SIGNATURE	OF APPLICANT, ATTO	RNEY, C	OR AGENT
Firm Name AVENTIS PHARMACEUTICA	LS INC.		
Signature Speed O : Rosa	1		
Printed name Jaseph ROSSI			
Date January 04, 2005		Reg. No.	47038
CERTIF	ICATE OF TRANSMISS	ION/MAI	ILING
I hereby certify that this correspondence is being fac sufficient postage as first class mail in an envelope a	iddressed to: Commissioner fo	or Patents, i	P.O. Box 1450, Alexandria, VA 22313-1450 on
the date shown below: (USPTO FAX NO. 703-872	-9306 ; Total No. of Pa	ges Transr	mitted: 18)
- The CA			
Typed or printed name Paul Irvine			Date January 04, 2005

This collection of information is required by 37 CPR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED **CENTRAL FAX CENTER** 

JAN. 4. 2005 2:51PM

AVENTIS US PAT DEPT

JAN 0 4 2005

NO. 1077 P. 2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GRAUPE, et al.

Examiner:

Robert Shaio

Art Unit:

1626

Application No.: 10/035,783 Filed: 12/24/2001

Compositions As Cathespin

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to

the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature

Inhibitors

Title: Novel Compounds and

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

 $\Box$ 

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

$\boxtimes$	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.					
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113					
		or a notice of allowance under §1.311, whichever occurs first.						
		(1)	The undersigned attorney certifies that each item of information contained in this					
			Information Disclosure Statement was cited in a communication from a foreign					
			patent office in a counterpart foreign application not more than three months prior					
	•		to the filing of this statement;					
		(2)	The undersigned attorney certifies that no item of information contained in this					
			Information Disclosure Statement was cited in a communication from a foreign					
			patent office in a counterpart foreign application or, to the knowledge of the					
			undersigned attorney after making reasonable inquiry, was known to any					
			individual designated in §1.56(c) more than three months prior to the filing of this					
			statement; or					
	$\boxtimes$	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in					
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is					
			authorized.					

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed on pages 1-13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case: U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and U.S. Patent Application Nos. 10/183,128, 10/294,526, 10/719,080, 10/787,367, 10/418,183 and US02/17922 (PCT application filed in the U.S. receiving office).

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement. However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,

Joseph D. Rossi, Reg. No. 47,038 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner: Robert Shaio

GRAUPE, et al.

Art Unit:

1626

Application No.: 10/035,783

Filed: 12/24/2001

Title: Novel Compounds and

Compositions As Cathespin

**Inhibitors** 

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

mey/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3410 Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

Please type a plus sign (+) inside this box 👈	Г	٦
	ı.	

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Subslik	de for form 1449A/PTC	)		Complete if Known			
1817	004471011	<b>D</b>		Application Number	10/035,783		
			CLOSURE	Filing Date	12/24/2001		
STA	<b>ITEMENT B</b>	Y A	PPLICANT	First Named Inventor	GRAUPE		
				Group Art Unit	1626		
(use as many sheets as necessary)				Examiner Name	Shaio		
Sheet	1	of	13	Attorney Docket Number	USAV2001/0081 - US - NP		

				U.S. PATENT DOCI	JMENTS	44
Examiner Inilials	Cite Na.1	U,S, Patent	Kind Gode <sup>2</sup> (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columna, Lines, Where Relevant Passages or Relevant Pages Appear
		4,927,809		STUBER, et al.	05-22-1990	
		5,424,325		ANDO, et al.	06-13-1995	
		5,486,623		ZIMMERMAN, et al.	01-23-1996	
		5,498,616		MALLANO, et al .	03-12-1996	
		5,847,135		BEMIS, et al.	12-08-1998	
		5,852,007		CHATTERJEE, et al.	12-22-1998	
		5,874,424		BATCHELOR, et al.	02-23-1999	
		5,998,390		RAMAMURTHY, et al.	12-07-1999	
		6,004,933		SPRUCE, et al.	12-21-1999	
		6,022,861		SCARBOROUGH, et al.	02-08-2000	
		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	<u> </u>
		6,455,502		BRYANT, et al.	09-24-2002	
		6,476,026		BRYANT, et al.	11-05-2002	
		6,492,362		GRAUPE, et al.	12-10-2002	
		6,506,733		BUYSSE	01-14-2003	•
		6,576,630		LINK, et al.	06-10-2003	

				FOR	EIGN PATENT DOCUMENT	វន		
Examiner Initials	Cile No.1		Foreign Patent Do	Kind Codes	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	Ī
	110.	Office		(if known)		MM-DD-YYYY	Figures Appear	T6
		EP	EP 0272671		KRANTZ, et al.	06-29-1988		
		EP	EP 0291234		EDWARDS, et al.	11-17-1998		T
		EP	EP 0355572		PAQUES, et al.	02-28-1990		$\Box$
		EP	EP 0376012		ALBRIGHT, et al.	07-04-1990		$\top$
		EP	EP 0419683		HARA, et al.	04-03-1991		
		EP	EP 0536399		OKUBO, et al.	04-01-1993		T
		ΕP	EP 0652009	1	DOVEY, et al.	10-05-1995		1
		EP	EP 0754454		KOBAYASHI, et al.	01-22-1997		
		JP	JP 06192199		RYOICHI, et al.	07-12-1994		
		JP	JP 42009133		IRIKURA, et al.	05-06-1967		

	ate
Signature Co	Considered

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chlef Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this rork Reduction Act			Pelent and Tradem	PTO/SB/08A (10-96) proved for use through 10/31/99. OMB 0651-0031 sark Office: U.S. DEPARTMENT OF COMMERCE on upless it contains a valid OMB control number,	+	
1		ule for form 1449A/i			Complete if Known			
	IN E	ODMATIO	N D		Application Number	10/035,783	ľ	
4				SCLOSURE	Filing Date	12/24/2001	ĺ	
	STA	ATEMENT	BY A	APPLICANT	First Named Inventor	GRAUPE	Í	
		<b></b> .			Group Art Unit	1626		
L		(use as many s	neets a	s necessary)	Examiner Name	Shaio	I	
- (	Sheet	2	of	13	Attorney Docket Number	USAV2001/0081 - US - NP		

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.1	U.S. Patent	Nind Codes (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		10/035,783		GRAUPE, et al.	12-24-2001				
		10/719,080		GRAUPE, et al.	11-21-2003				
		US02/17922		GRAUPE, et al.	11-24-2003	<del></del>			
	_	10/787,967		GRAUPE, et al.	9-16-2002				
		10/418,183		LI, et al.	10-23-2003				
		:							
			-						
			-						
				•					
						***			
1		1	11			·			

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No.1	Office	Foreign Patent Do Number	Cument Kind Code <sup>5</sup> (If known)	Name of Palentee or Applicant of Cited Document	Date of Publication of Cited Decument MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		JP	JP 63303868		YO\$HIDA, et al.	12-08-1988		T
1		WO	WO 00/48992		TUCKER, et al.	08-24-2000		
		wo	WO 00/49007		TUCKER, et al.	08-24-2000	* * * * * * * * * * * * * * * * * * * *	1
		WO	WO 00/49008		TUCKER, et al.	09-24-2000	·	1
		wo	WO 00/51998		CYWIN, et al.	09-08-2000		1
		WO	WO 00/59881		SINGH, et al.	10-12-2000	· ·	1
		WO	WO 00/69855		QUIBELL, et al.	11-23-2000		
		WO	WO 01/09110		BEKKALI, et al.	02-08-2001	-	$\top$
		wo	WO 01/19796		GRAUPE, et al.	09-22-2001		
		wo	WO 01/19808		GRAUPE	03-22-2001		

Examiner	···	Date	
Signature		Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard \$T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademerk Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not obtain is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this i		rsons are required to re	Aor Patent and Traderr Spond to a collection of Informati	PTO/SB/06A (10-96)  DOWNOR for use through 10/31/39, OMB 0851-0031  Bark Office: U.S. DEPARTMENT OF COMMERCE  On Upless it contains a valid OMB control number.	_
Í	Substitu	ute for form 1449A/F	PTO		C	complete if Known	
	INTE	ODBARTIO	N DIGG	· COURT	Application Number	10/035,783	
- 1		ORMATIO			Filing Dato	12/24/2001	
	STA	ATEMENT	BY API	PLICANT	First Named Inventor	GRAUPE	
		(110.4			Group Art Unit	1626	
- !		(USO as many s	heets as nec	cessary)	Examiner Name	Shaio	
•	Sheet	3	of	13	Attorney Docket Number	USAV2001/0081 - US - NP	

				U.S. PATENT DOC	UMENTS		
Examiner	Cite	U.S. Paler	nt Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials"	No.1	Number	(if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant  Figures Appear	
'	- ' -			•			
			"			· · · · · · · · · · · · · · · · · · ·	
						•	
		·					
						<del></del>	
				•			
						· · · · · · · · · · · · · · · · · · ·	
	j					<u>.</u>	
				,	1		
				•		M	
	1					··	

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner	Cile		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	Î
Initiala*		Office	3 Number	Kind Code <sup>5</sup> (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	TØ
		wo	WO 01/19816		EMMANUEL, et al.	03-22-2001		
	_	wo	WO 01/30772		TUCKER, et al.	05-03-2001		П
		WO	WO 01/55125		BOZSING, et al.	08-02-2001		1
		wo	WO 01/58886		MISSBACH, M	08-16-2001		
<u> </u>		WO	WO 95/13069		MORRIELLO, et al.	05-18-1995		$\top$
		wo	WO 95/15809		JENKINS, et al.	06-08-1995		
		WO	WO 95/24382		HALLINAN, et al.	09-14-1995		1
		9	WO 96/21655		PEET, et al.	07-18-1998		1
		80	WO 96/30353		PALMER, et al	10-03-1998		1
		W <sub>O</sub>	WO 96/40647		ZIMMERMAN, et al.	12-19-1998		$\top$

Examiner	Date	
Signature	Considered	
<b>`</b>		

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precade the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the incided asse. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this ork Reduction Act o	<u> </u>	mone are required to n	App Patent and Tradem espond to a collection of information	PTO/SB/08A (10-96)  proved for use through 10/31/99. OMB 0551-0031  lark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
1	Substitu	ile for form 1449A/F	то		C	complete if Known
1	INIT	ODMATIO	N DIGG	LOCUE	Application Number	10/035,783
		ORMATIO			Filing Date	12/24/2001
- 1	STA	TEMENT	BY AP	PLICANT	First Named Inventor	GRAUPE
					Group Art Unit	1626
L		(use as many s	heels es ne	cessary)	Examiner Name	Shalo
(	Sheet	4	of	13	Altomey Docket Number	USAV2001/0081 - US - NP

				U.S. PATENT DOC	JMENTS	
Examiner Initials"	Cite No.1	U.S. Pater Number	Kind Code <sup>2</sup> (#Impwn)	Name of Patentse or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pagos, Columna, Lines, Whore Relevant Passages or Relevant Figures Appear
!						
				•		
		•				
		•				
				•		•
				·		

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner	Examiner Cite		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
iniliala*	No,1	Office	Number 1	Kind Code <sup>8</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	aT a
		wo	WO 96/40744		MARLOWE, et al.	12-19-1996		
		wo	WO 96/41638		DOLLE, et al.	12-27-1998		
		wo	WO 97/03679		MALLANO, et al.	02-06-1997		
		WO	WO 98/01133		AIBE, et al.	01-15-1998		
		WO	WO 98/01428		DOMINGUEZ, et al.	01-15-1998		
		wo	WO 98/05336		MARQUIS, et al.	02-12-1998		1
		wo	WO 98/08802		YAMASHITA, et al.	03-05-1998		
		WO	WO 98/08867		SHIONOGI, et al.	03-05-1998		
		8	WO 98/21188		PRESTON, et al.	05-22-1998		
		WO	WO 98/23588		FLOYD, C.	06-04-1998		

Examiner	•	Date	
Signature		Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the petent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is altached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this rank Reduction Act			App Palent and Tradom espond to a collection of informatic	PTC/SB/08A (10-96)  foved for use through 10/31/99, OMB 0851-0031  ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number,	
- (	Substit	Jie for form 1449A/	PTO		Complete If Known		
	ANI CO				Application Number	10/035,783	
				SCLOSURE	Filing Date	12/24/2001	
	STA	TEMENT	BY A	APPLICANT	First Named Inventor	GRAUPE	
			_		Group Art Unit	1626	
L		(USO BS MBNy S	sheets a:	s necessary)	Examiner Name	Shaio	
	Sheet	5	of	13	Attorney Docket Number	USAV2001/0081 - US - NP	

				U.S. PATENT DOCI	JMENTS	
Examiner	Cite Na.1	U.S. Pater	it Document	Name of Patentce or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevent
			of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Expues Appear	
			1_1			
				· · · · · · · · · · · · · · · · · · ·		
1				•		
				•		
						· · · · · · · · · · · · · · · · · · ·
						· · · · · · · · · · · · · · · · · · ·
_						·
	_			· · · · · · · · · · · · · · · · · · ·		
				<u> </u>		
					<u> </u>	,
				-	· · ·	
			11			
					1	

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Inilials	Cite No.1	Foreign Patent Document  Office <sup>2</sup> Number Kind Code <sup>2</sup> (# known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Finures Appear	Tå.	
		WO WO 98/49190			SPRUCE, et al.	11-05-1998		
		wo	WO 99/24460		ALTMANN, et al.	05-20-1999		
						<del>                                     </del>		$\vdash$
	•					<del>                                     </del>	~	-
						<del>                                     </del>		Н

Examiner		Date	
Signature		Considered	
	· · · · · · · · · · · · · · · · · · ·	<u> </u>	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the IndMdual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patants, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) Inside t work Reduction A				pro/SB/08B (10-96) proved for use through 10/31/99. OMB 0561-0031 park Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a yatid OMB control number.
	le for form 1449B/				omplete if Known
100				Application Number	10/035,783
INFO	)KWA H	אט אכ	SCLOSURE	Filing Date	12/24/2001
I STA	TEMENT	BY A	PPLICANT	First Named Inventor	GRAUPE
1				Group Art Unit	1626
	(use as mar	ny sheets a	s necessary)	Examiner Name	Shaio
Sheet	6	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

	T	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
xaminer nitials*	Cite No.1	item (book, magazine, journal, serial, symposium, cetalog, etc.), date, page(a), volume-issuo number(s), publisher, city and/or country where published.	٩
		ADAMS, et al., Potent and Selective Inhibitors of the Protessom: Dipeptidyl Boronic Acids, Biooganic & Medicinal Chemistry Letters, 8: 333-338 (1998).	
		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, etable inhibitors of dipeptidyl peptidase IV, Bioorganic & Med. Chem. Letters, B,Oxford, 6(22):2745-2748 (1996).	
		BERGEMAN, et al., Studies on the reactivity of alphacyano.alpha-lsocyano alkanoates. Versitile synthons for the assembly of imidazolea, Helv.Chim. ACTA, 82(6):909-918 (1999).	
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cystelnyl, Bloorg. Med. Chem. Lett. vol. 8, pp. 993-998, 1998	
		BROMME, et al., Potent inactivation of Cathepsins S and L , Biol. Chem. Hoppe—Seyler. vol. 375, No. 5, pp. 343-347, 1994.	
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p. 2863-2866 (1998).	
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-36 (1999).	
		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Bio.chemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).	
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Portine Pancreatic Elastase and Ao-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1854-1863 (1992).	
		EVOLI, et al., abstract only, Drugs, 1995, 52(5), 662-70	
	ľ	- V = 11, 0.1 ± 11, 12 ± 12, 10 ± 10, 10 ± 10, 10 ± 10	

Examiner	•	Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number, <sup>2</sup> Applicant is to place a check mark here if English tanguage Translation is attached.

	us sign (+) Inside this work Reduction Act o		·	Api Palent and Tradon spond to a collection of informati	PTC/SB/088 (10-96) proved for use through 10/31/99, OMB 0651-0031 hark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
1	te for form 1449B/PT			Complete if Known		
IN ITE	20114710			Application Number	10/035,783	
INFO	JRIMA HO	NL	DISCLOSURE	Filing Date	12/24/2001	
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE	
			,	Group Art Unit	1626	
	(use as many :	shee	s as necessary)	Examiner Name	Shaio	
Sheet	7	of	13	Altorney Docket Number	USAV2001/0081 - US - NP	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	т.
Examiner Inidals	Cite No.1	item (book, magazine, journel, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group Into other functionalilles via the papain:nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council. Ollawa, 69(8):1268-1297 (1991).	
•		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys, Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and )achalasla) methyl ketones as inhibitors of the enzyme. Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett. 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha(acylamino) nitrites and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-83.	-
		KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent , Biochemistry. vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	-
		LI, et al., Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Bioph., 323(1)148-154 (1995).	

Examiner	Date	
Signature ,	 Considered	

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	lus sign (+) Inside thi Work Reduction Act		ليسيا		PTO/SB/06B (10-86) proved for use through 10/31/89. OMB 0651-0031 nark Office: U.S. DEPARTMENT OF COMMERCE ton unless it contains a valid OMB control number,	
Substite	ale for form 1449B/P	ΤΦ		Complete if Known		
DIE			1001 001105	Application Number	10/035,783	
			ISCLOSURE	Filing Date	12/24/2001	
STA	TEMENT	BY	APPLIÇANT	First Named Inventor	GRAUPE	
				Group Art Unit	1626	
	(use as many	sheet	s as necessary)	Examiner Name	Shaio	
Sheet	. 8	of	13	Alterney Docket Number	USAV2001/0081 - US - NP	

	f	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Inivals*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the frem (book, magazine, journal, señal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
		LIPSHUTZ, et al., Chiral induction in orginally racemic amino acids via 5-acyl and 5-acyloxyaminocxazoles, lsr, J. Chem. 27(1):49-55 (1986). abstract.	
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, . Am. Chem. Soc., 105(28):7703-7713 (1983).	
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).	
		MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, Chemical Abstracts, 7:4 561-568 (1999).	!
		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 134(1):105-110 (1997).	
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives.sup.1, J. Med. Chem., 29: 333-341 (1986).	
	- 1	MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur praparativen herstellung. poly (dipeptamidinium) salts: definition and methods of preparation, Helvitica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1988).	
		NIPPON, K., Patent Abstracts of Japan, Publication No. 62301858, 013(137)(1988), abstract.	
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, Tetrahedron, 48(24):8627-8290 (1990).	
		OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).	

Examiner		Date	
	4		
Signature		Considered	
	<del></del>	O O C PO	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Weahington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&#</sup>x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	lus sign (+) inslde t work Reduction Ac			Datest and Tradem	FTO/SB/06B (10-96) proved for use through 10/31/99. OMB 0661-0031 park Office; U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
Substitu	ite for form 14498/	PTQ		Complete if Known		
I INC		<b>.</b>	1001 001	Application Number	10/035,783	
			SCLOSURE	Fillng Date	12/24/2001	
STA	TEMENT	<b>BY</b>	APPLICANT	First Named Inventor	GRAUPE	
				Group Art Unit	1626	
	(use as man	y sheet	s as necessary)	Examiner Name	Shaio	
Sheet	9	of	13	Attorney Dockel Number	USAV2001/0081 - US - NP	

-	I	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T-
Examiner Initials	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		PICKEN, et al., inhibition of bovine cathepsin B by amino acid-derived nitrites, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of colpain and cathepsin B , Biochem. J. vol. 268, pp. 759-762, 1992	
_		POLMAN, et al., Drug treatment of multiple sclerosis , BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathesin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 957-366 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteins Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1986	
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofuctionalized enamines and monofuntionalized methyl ketone dedvatives form thioamides via epiculfides and thioiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
· · · · · · · · · · · · · · · · · · ·		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Haptic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thienyl)imidazole Derivatives with Antinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8); 3111-3120 (1998).	•
		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bloorganic & Medicinal Chemnistry Letters, 6:24 3009-3112 (1996).	,

Examiner	Date	
Signature	Considered	
	Ochlaideled	<u>-                                    </u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington. DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	us sign (+) inside t				PTO/SB/08B (10-98) proved for use through 10/31/99. OMB 0631-0031 park Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
7	te for form 1449B/			Complete if Known		
iNE	3D34A74	<b>~~</b>	1001 0011	Application Number	10/035,783	
			ISCLOSURE	Filing Date	12/24/2001	
STA	TEMENT	<b>FBY</b>	APPLICANT	First Named Inventor	GRAUPE	
				Group Art Unit	1626	
ļ	(use as mar	ıy sheet	s as necessary)	Examiner Name	Shaio	
Sheet	10	of	13	Altomey Docket Number	USAV2001/0081 - US - NP	

	_	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite Na,1								
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).							
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).							
		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitrites, Stud. Univ. Babes-Bolyal, Ser. Chem., 19(2):31-5 (English abstract of article in Romanian) (1966).							
		VARGHESE, The structure and resonance Raman spectrastructure correlations for methyloxycarbony-L-phenylalanyi-L-alanine ethyl dithloester, Can. J. Chem., 64(8):1668-1673 (1986).							
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottomycine 81 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.							
		, Derwant Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).							
		· · · · · · · · · · · · · · · · · · ·							
1			<u> </u>						
xaminer Signature		Date Considered							

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique dilation designation number. <sup>2</sup> Applicant is to place a check mark here If English language Translation is attached,

		sign (+) inside this took Reduction Act o		en at beniupen ens snacne	App Patent and Tradem spond to a collection of informetic	PTO/SB/08A (10-96)  proved for use through 10/31/99, OMB 0651-0031  Bork Office: U.S. DEPARTMENT OF COMMERCE  on unless it contains a valid OMB control number.
- 7		ite for form 1449A/P				omplete if Known
	INIE	ORMATIO	N DICC	N ACUBE	Application Number	10/035,783
					Filing Date	12/24/2001
- 1	SIA	TEMENT	BY AP	PLICANT	First Named Inventor	GRAUPE
		///c			Group Art Unit	1626
		(use as many sh	ieera as ne	cessary)	Examiner Name	Shaio
SI	heet	11	of	13	Atterney Docket Number	USAV2001/0081 - US - NP

				U.S. PATENT DOC	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent Number	Cocument Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pagas, Columns, Lines. Where Rolevant Passages or Rolevant Figures Appear
		09/927,188		CAI, et al.	08-10-2001	Figure Appear
		09/927,324		BUTLER, et al.	08-10-2001	
		09/928,122		BREITENBUCHER, et al.	08-10-2001	
		09/946,214		GU, et al.	09-05-2001	
		10/042,565		QUIBELL, et al.	11-16-2001	<del></del>
		10/148,612		OHMOTO, et al.	08-21-2002	
		10/148,613		OHMOTO, et al.	08-28-2002	<del></del>
		10/181,713		OHMOTO, et al.	07-22-2002	·
		10/181,799		OHMOTO, et al.	07-23-2002	
		10/231,425		BUXTON, et al	08-28-2002	
		10/256,512		BEKKALI, et al.	09-27-2002	
		10/258,053		CUMMINGS, et al.	10-17-2002	
		10/275,583		COWEN, et al.	11-07-2002	
		10/279,424		BEKKALI, et al.	10-24-2002	· · · · · · · · · · · · · · · · · · ·
		10/466,385		QUIBELL, et al.	01-08-2004	
		6,015,791		GYORKOS, et al.	01-18-2000	
		6,608,057		CYWIN, et al.	08-18-2003	
					<del>                                     </del>	<u> </u>
					1	

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials	Cila No.1	Office	Foreign Patent Doc  Number	Ument Kind Cade <sup>2</sup> (if known)	Name of Patentee or Applicant of Chied Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columne, Lines, Whore Relevant Pessages or Relevant	Te
		JP	JP 2001-011037		SATO, et al.	01-18-2001	Figures Appear	┿
		JP	JP 2001-055366		SATO, et al.	02-27-2001		$\dagger$
		WO	WO00/59881		SINGH, et al.	10-12-2000		+
		WO	WC01/09169		SINGH, et al.	02-08-2001	······································	1
		WO	WO02/057248		QUIBELL, et al.	07-25-2002	····	1-
		WO	WO02/057249		QUIBELL, M	07-25-2002		1-
		wo	WO02/057270		QUIBELL, M	07-25-2002		t
		wo	WO02/096892		OHMOTO, et al.	05-30-2002	· · · ·	+
		wo	WO02/100849		HICKEY, et al.	12-19-2002		<del> </del>
		WO	WO02/20485		BEKKALI, et al.	03-14-2002		+

Examiner	Date
Signature	Considered
	30.10.201.00

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that tasued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) inside tl work Reduction Ac				PTO/SB/08B (10-96) Proved for use through 10/31/99. OMB 0651-0031 Bark Office; U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
Substitu	ite for form 1449B/i	РТО		Co	omplete if Known
INE	ODBA A TIC		1001 001105	Application Number	10/035,783
			ISCLOSURE	Filing Date	12/24/2001
STA	TEMENT	BY	<b>APPLICANT</b>	First Named Inventor	GRAUPE
	•			Group Art Unit	1626
	(use as man	y sheets	as necessary)	Examiner Name	Shalo
Sheet	12	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	_						
		publisher, city and/or country where published.							
		CHAPMAN, et al., Emerging Roles for Cysteine Proteases In Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.							
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-208.							
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cycllo Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202.	-						
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K., Bioorg, Med. Chem. Lett.; 2001; 11(2); pp.195-198.							
		GREENSPAN, et al., Identification of Dipeptidyl Nitrlles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Cham.; 2001; 44; pp.4524-4534.							
		LOWE, et al., Kinetia Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.							
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolylic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.							
		MARQUIS, et al., Azeanone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(9); op.1380-1395.							
		NAKAGAWA, et al., Imparled Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.							
	-	OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.							
		·							

E			
Examiner	•	Date	
Signature			
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not ctation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a chack mark here if English language Translation is attached.

	us sign (+) inside this work Reduction Act			App Patent and Tradem spond to a collection of information	PTO/SB/088 (10-96) proved for use through 10/31/99. OMB 0651-0031 perk Office: U.S. DEPARTMENT OF COMMERGE on unless it contains a valid OMB control number.
Substitu	te for form 1449B/P7	го		Co	omplete if Known
				Application Number	10/035,783
INFO	DRMATIO	NC	ISCLOSURE	Filing Date	12/24/2001
I STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
			7.1. · L. Q. (1.1.	Group Art Unit	1626
	(use as many	sheet	s as necessary)	Examiner Name	Shaio
Sheet	13	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published,	L <sub>3</sub>
		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastinolytic Cystelne Protease, J. Blol. Chem.; 1992; 267; pp.7258-7262.	
		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517.	
		VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest; 1998; 101(10); pp.2351-2363.	
• •			
1			
Examine Signatur		Date Considered	

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Palent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.